Search

Your search keyword '"for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)"' showing total 4 results
Start Over Author "for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)" Topic non-alcoholic fatty liver disease
4 results on '"for the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)"'

1. Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease.

Author

Harlow, Kathryn E, Africa, Jonathan A, Wells, Alan, Belt, Patricia H, Behling, Cynthia A, Jain, Ajay K, Molleston, Jean P, Newton, Kimberly P, Rosenthal, Philip, Vos, Miriam B, Xanthakos, Stavra A, Lavine, Joel E, Schwimmer, Jeffrey B, and Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)

Subjects
Nonalcoholic Steatohepatitis Clinical Research Network, Humans, Hypercholesterolemia, Hypertriglyceridemia, Triglycerides, Diet, Longitudinal Studies, Life Style, Child, Female, Male, Cholesterol, LDL, Non-alcoholic Fatty Liver Disease, NAFLD, cardiovascular, diet, dyslipidemia, pediatric, statin, Liver Disease, Atherosclerosis, Pediatric, Nutrition, Obesity, Heart Disease, Cardiovascular, Chronic Liver Disease and Cirrhosis, Digestive Diseases, Prevention, Metabolic and endocrine, Pediatrics, Human Movement and Sports Sciences, Paediatrics and Reproductive Medicine
Abstract

OBJECTIVE:To determine the percentage of children with nonalcoholic fatty liver disease (NAFLD) in whom intervention for low-density lipoprotein cholesterol or triglycerides was indicated based on National Heart, Lung, and Blood Institute guidelines. STUDY DESIGN:This multicenter, longitudinal cohort study included children with NAFLD enrolled in the National Institute of Diabetes and Digestive and Kidney Diseases Nonalcoholic Steatohepatitis Clinical Research Network. Fasting lipid profiles were obtained at diagnosis. Standardized dietary recommendations were provided. After 1 year, lipid profiles were repeated and interpreted according to National Heart, Lung, and Blood Institute Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction. Main outcomes were meeting criteria for clinically actionable dyslipidemia at baseline, and either achieving lipid goal at follow-up or meeting criteria for ongoing intervention. RESULTS:There were 585 participants, with a mean age of 12.8 years. The prevalence of children warranting intervention for low-density lipoprotein cholesterol at baseline was 14%. After 1 year of recommended dietary changes, 51% achieved goal low-density lipoprotein cholesterol, 27% qualified for enhanced dietary and lifestyle modifications, and 22% met criteria for pharmacologic intervention. Elevated triglycerides were more prevalent, with 51% meeting criteria for intervention. At 1 year, 25% achieved goal triglycerides with diet and lifestyle changes, 38% met criteria for advanced dietary modifications, and 37% qualified for antihyperlipidemic medications. CONCLUSIONS:More than one-half of children with NAFLD met intervention thresholds for dyslipidemia. Based on the burden of clinically relevant dyslipidemia, lipid screening in children with NAFLD is warranted. Clinicians caring for children with NAFLD should be familiar with lipid management.

Published
2018

2. Alanine Aminotransferase and Gamma-Glutamyl Transpeptidase Predict Histologic Improvement in Pediatric Nonalcoholic Steatohepatitis

Author

Newton, Kimberly P, Lavine, Joel E, Wilson, Laura, Behling, Cynthia, Vos, Miriam B, Molleston, Jean P, Rosenthal, Philip, Miloh, Tamir, Fishbein, Mark H, Jain, Ajay K, Murray, Karen F, Schwimmer, Jeffrey B, and Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)

Subjects
Male, Adolescent, Cysteamine, Clinical Trials and Supportive Activities, Chronic Liver Disease and Cirrhosis, Clinical Sciences, Immunology, Medical Biochemistry and Metabolomics, Oral and gastrointestinal, Hepatitis, Predictive Value of Tests, Non-alcoholic Fatty Liver Disease, Clinical Research, Humans, Aspartate Aminotransferases, Child, Gastroenterology & Hepatology, Liver Disease, Remission Induction, Alanine Transaminase, gamma-Glutamyltransferase, Prognosis, Treatment Outcome, Good Health and Well Being, Liver, Delayed-Action Preparations, Nonalcoholic Steatohepatitis Clinical Research Network, Female, Digestive Diseases
Abstract

Background and aimsPredictive, noninvasive tools are needed to monitor key features of nonalcoholic fatty liver disease (NAFLD) in children that relate to improvement in liver histology. The purpose of this study was to evaluate the relationship between liver chemistries and liver histology using data from the CyNCh (Cysteamine Bitartrate Delayed-Release for the Treatment of NAFLD in Children) clinical trial.Approach and resultsThis study included 146 children. Improvement in liver histology, defined as decrease in nonalcoholic fatty liver disease (NAFLD) Activity Score ≥2 points without worsening of fibrosis, occurred in 43 participants (30%). There were 46 participants with borderline zone 1 nonalcoholic steatohepatitis (NASH) at baseline, with resolution in 28% (12 of 46). Multivariate models were constructed using baseline and change in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) at 52weeks, for improvement in (1) liver histology primary outcome, (2) borderline zone 1 NASH, and (3) fibrosis. For improvement in histology, the model (P&nbsp

Published
2021

3. Haptoglobin 2 Allele is Associated With Histologic Response to Vitamin E in Subjects With Nonalcoholic Steatohepatitis

Author

Banini, Bubu A, Cazanave, Sophie C, Yates, Katherine P, Asgharpour, Amon, Vincent, Robert, Mirshahi, Faridoddin, Le, Peter, Contos, Melissa J, Tonascia, James, Chalasani, Naga P, Kowdley, Kris V, McCullough, Arthur J, Behling, Cynthia A, Schwimmer, Jeffrey B, Lavine, Joel E, Sanyal, Arun J, and Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)

Subjects
Adult, Male, nonalcoholic fatty liver disease, Genotype, Clinical Trials and Supportive Activities, Chronic Liver Disease and Cirrhosis, Clinical Sciences, vitamin E, haptoglobin genotype, Oral and gastrointestinal, Hepatitis, Non-alcoholic Fatty Liver Disease, Clinical Research, Complementary and Integrative Health, Humans, oxidative stress, nonalcoholic steatohepatitis, Alleles, Randomized Controlled Trials as Topic, Haptoglobins, Gastroenterology & Hepatology, Liver Disease, Treatment Outcome, Nonalcoholic Steatohepatitis Clinical Research Network, Female, Digestive Diseases
Abstract

BackgroundHaptoglobin (Hp) genotype has been linked to oxidative stress and cardiovascular outcomes in response to vitamin E (VitE) among patients with diabetes mellitus. Its effect on histologic response to VitE in nonalcoholic steatohepatitis (NASH) is unknown.GoalsOur objective was to determine if Hp genotype associates with response to VitE in patients with NASH.StudyA post hoc analysis of 228 patients receiving VitE or placebo in 2 clinical trials was performed. Regression analysis was used to assess the effect of VitE versus placebo, by Hp genotype (1-1, 2-1, or 2-2), on histologic features and laboratory markers of nonalcoholic fatty liver disease, comparing baseline to end of treatment values. An interaction term was included in the regression models to assess differential treatment effect across Hp genotype.ResultsHp 2-2 patients treated with VitE versus placebo showed significant histologic improvement (51% vs. 20%; OR=4.2; P=0.006), resolution of steatohepatitis (44% vs. 12%; OR=6.2; P=0.009), decrease in nonalcoholic fatty liver disease Activity Score (NAS) (-2.2 vs. -0.6; P=0.001), and decrease in liver enzymes alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and γ-glutamyl transpeptidase. Hp 2-1 patients on VitE versus placebo showed improved resolution of steatohepatitis, NAS and liver enzymes. Hp 1-1 patients showed no significant improvement in histology or liver enzymes. VitE had no effect on fibrosis stage in any group. Regression analysis showed incremental benefit of having Hp 2-2 or 2-1 versus 1-1 for all liver enzyme.ConclusionsHp 2 allele is associated with greater histologic and biological improvement in NASH with VitE treatment compared with the Hp 1 allele.

Published
2019

4. Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children

Author

Newton, Kimberly P, Feldman, Haruna S, Chambers, Christina D, Wilson, Laura, Behling, Cynthia, Clark, Jeanne M, Molleston, Jean P, Chalasani, Naga, Sanyal, Arun J, Fishbein, Mark H, Lavine, Joel E, Schwimmer, Jeffrey B, and Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN)

Subjects
Male, nonalcoholic fatty liver disease, obesity, Adolescent, Biopsy, Chronic Liver Disease and Cirrhosis, Low Birth Weight and Health of the Newborn, Pediatrics, Oral and gastrointestinal, Hepatitis, Paediatrics and Reproductive Medicine, Databases, children, Risk Factors, Non-alcoholic Fatty Liver Disease, Clinical Research, Preterm, Infant Mortality, Humans, Birth Weight, nonalcoholic steatohepatitis, Child, Factual, Pediatric, Liver Disease, Prevention, Low Birth Weight, Infant, Human Movement and Sports Sciences, Perinatal Period - Conditions Originating in Perinatal Period, United States, Cross-Sectional Studies, Liver, Postmature, Nonalcoholic Steatohepatitis Clinical Research Network, Female, epidemiology, Digestive Diseases
Abstract

ObjectivesTo examine the distribution of birth weight in children with nonalcoholic fatty liver disease (NAFLD) compared with the general US population, and to investigate the relationship between birth weight and severity of NAFLD.Study designA multicenter, cross-sectional study of children with biopsy-proven NAFLD enrolled in the Nonalcoholic Steatohepatitis Clinical Research Network Database. Birth weight was categorized as low birth weight (LBW), normal birth weight (NBW), or high birth weight (HBW) and compared with the birth weight distribution in the general US population. The severity of liver histology was assessed by birth weight category.ResultsChildren with NAFLD (n = 538) had overrepresentation of both LBW and HBW compared with the general US population (LBW, 9.3%; NBW, 75.8%; HBW, 14.9% vs LBW, 6.1%; NBW, 83.5%; HBW 10.5%; P

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results